Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- My bad: I left out Fox Chase
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Edward Copeland, surgeon and breast cancer expert, dies at 86